Evaluation, Treatment, and Natural History of Children With Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00001686|
Recruitment Status : Enrolling by invitation
First Posted : November 4, 1999
Last Update Posted : May 18, 2018
|Condition or disease|
|Ewing's Sarcoma Leukemia Lymphoma Brain Tumors Rhabdomyosarcoma|
Children and adults are referred to the Pediatric Oncology Branch (POB) for possible enrollment in clinical protocols for the treatment of cancer. While some children are not eligible for a specific protocol, they may present with disease manifestations that offer the potential for important new insights into the pathogenesis or clinical behavior of their underlying disease. In addition, children who have completed participation in a clinical protocol but do not currently have therapeutic protocol alternatives may continue to provide POB with important information. Diseases of interest to the POB include, but are not limited to lymphoma, brain tumors, Ewings sarcoma, leukemia, neuroectodermal tumors, osteosarcoma, and rhabdomyosarcoma. Hence, serial clinical evaluation of such patients, including the performance of clinical, laboratory, and diagnostic studies to help elucidate longitudinally the underlying disease mechanisms, and when clinically indicated standard care therapies, will assist POB meet its overall mission.
To be able to follow and evaluate children and adults with cancer or pre-cancer syndromes referred to the Pediatric Oncology Branch who present with disease manifestations that lend themselves to clinical evaluation and are of unique scientific import.
Patients who are evaluated by the Pediatric Oncology Branch and are:
- Children and adults with cancer (or a pre-cancer syndrome), with disease manifestations of special interest to Pediatric Oncology Branch investigators.
- Patients must be greater than or equal to 2 years and less than or equal to 40 years of age at the time of study enrollment.
The medical procedures or tests will be selected for each patient on the basis of his/her individual diagnosis (or presumed diagnosis). When clinically indicated, standard therapy will be administered and patients will be followed according to standard medical practice. Specimens may be collected for clinical care purposes only to evaluate the patient s status. No investigational tests, drugs or therapies will be administered in this protocol.
|Study Type :||Observational|
|Actual Enrollment :||408 participants|
|Official Title:||Treatment of Children With Cancer|
|Study Start Date :||December 3, 1997|
1 -Cohort A
Children and adults with cancer (or a pre-cancer syndrome), between the age(s) of 2 years - 40 years, who present with disease manifestations of special interest to POB investigators.
- Evaluate children and adults with cancer [ Time Frame: End of treatment ]evaluate longitudinally children and adults with cancer referred to the Pediatric Oncology Branch (POB) who present with disease manifestations that lend themselves to clinical evaluation and are of unique scientific importance
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001686
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Brigitte C Widemann, M.D.||National Cancer Institute (NCI)|